Thyroid cancer is the most common endocrine malignancy with an estimated 43,800 new
cases to be diagnosed in 2022 and representing the 7th most common cancer in women …

Simple Summary The aim of this review is to provide a general overview about the
molecular markers (mutations and alterations) of thyroid cancers, present several molecular …

Abstract Context The Afirma® GSC aids in risk stratifying indeterminate thyroid nodule
cytology (ITN). The 2018 GSC validation study (VS) reported a sensitivity (SN) of 91 …

Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer. Particularly
the incidence of small clinically indolent tumors has been increasing significantly during the …

Background: Since the noninvasive follicular thyroid neoplasm with papillary-like nuclear
features (NIFTPs) was introduced in 2016, most retrospective studies have included cases …

Thyroid nodules are quite common, and the determination of a nodule of concern is
complex, involving serum testing, radiology and, in some cases, pathological evaluation. For …

Thyroid cancer is the most common malignancy of the endocrine system. Fine-needle
aspiration (FNA) biopsy of thyroid nodules has become the gold standard procedure, in …

Abstract Background Indeterminate thyroid nodules (Bethesda III) are challenging to
characterize without diagnostic surgery. Auxiliary strategies including molecular analysis …

Background: An accurate preoperative workup of cytologically indeterminate thyroid nodules
(ITN) may rule out malignancy and avoid diagnostic surgery for benign nodules. This study …

Importance Molecular testing is commonly used in the diagnosis of thyroid nodules with
indeterminate cytology. The role of molecular testing in prognosticating oncologic outcomes …